Literature DB >> 16314942

Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis.

T Leyhe1, R Schüle, F Schwärzler, T Gasser, T Haarmeier.   

Abstract

Memory loss can be a symptom of paraneoplastic limbic encephalitis (PLE) a neuropsychiatric disorder associated mostly with small-cell lung cancer and anti-Hu antibodies or with testicular tumors and anti-Ma2 antibodies. We present the case of a patient with temporal coincidence of beginning cognitive decline and diagnosis of a carcinoma of the prostate in whom we diagnosed anti-Ma1/Ma2-positive PLE. The tumor had been completely resected but memory impairment further deteriorated. As the effective treatment of the cancer is considered as the most efficient treatment of a paraneoplastic neurological syndrome (PNS) a second neoplasia was suspected in the patient. By the aid of whole body positron emission tomography with 18-fluorine fluoro-2-deoxy-glucose (FDG-PET) an adenocarcinoma of the cecum could be detected. Two months after surgery anti-Ma antibodies were negative. We conclude that a second neoplasia should be considered, if effective cancer treatment does not lead to improvement or stabilisation of a PNS. Tumor search should be exhaustive and include PET when conventional imaging fails to show a malignancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314942     DOI: 10.1007/s11060-005-9052-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

1.  Paraneoplastic subacute encephalitis caused by adenocarcinoma of prostate: a clinico-pathological case report.

Authors:  P J Modrego; A Cay; M A Pina; A Monge
Journal:  Acta Neurol Scand       Date:  2002-04       Impact factor: 3.209

2.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

3.  A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.

Authors:  R Voltz; S H Gultekin; M R Rosenfeld; E Gerstner; J Eichen; J B Posner; J Dalmau
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

4.  Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Authors:  F Hulstaert; K Blennow; A Ivanoiu; H C Schoonderwaldt; M Riemenschneider; P P De Deyn; C Bancher; P Cras; J Wiltfang; P D Mehta; K Iqbal; H Pottel; E Vanmechelen; H Vanderstichele
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

5.  Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders

Authors: 
Journal:  Ann Neurol       Date:  1999-11       Impact factor: 10.422

6.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 7.  Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy.

Authors:  Raymond Voltz
Journal:  Lancet Neurol       Date:  2002-09       Impact factor: 44.182

8.  Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.

Authors:  Rainer Linke; Mira Schroeder; Thomas Helmberger; Raymond Voltz
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

9.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501

10.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

View more
  3 in total

Review 1.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

2.  Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.

Authors:  A Storstein; M Raspotnig; R Vitaliani; B Giometto; F Graus; W Grisold; J Honnorat; C A Vedeler
Journal:  J Neurol       Date:  2016-03-23       Impact factor: 4.849

3.  Two cases of paraneoplastic limbic encephalitis associated with small cell lung cancer and a literature review.

Authors:  Li Xu; Jianguo Hu; Qiming Chen
Journal:  Exp Ther Med       Date:  2014-12-16       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.